Heavy Trading On Dyax (DYAX) Before Market Open
Trade-Ideas LLC identified
(
) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Dyax as such a stock due to the following factors:
- DYAX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $63.2 million.
- DYAX traded 944,051 shares today in the pre-market hours as of 7:42 AM, representing 55.2% of its average daily volume.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in DYAX with the Ticky from Trade-Ideas. See the FREE profile for DYAX NOW at Trade-Ideas
More details on DYAX:
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. Currently there are 7 analysts that rate Dyax a buy, no analysts rate it a sell, and 1 rates it a hold.
The average volume for Dyax has been 1.4 million shares per day over the past 30 days. Dyax has a market cap of $4.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.29 and a short float of 5.6% with 4.36 days to cover. Shares are up 96.7% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Dyax as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share.
Highlights from the ratings report include:
- DYAX's revenue growth has slightly outpaced the industry average of 5.2%. Since the same quarter one year prior, revenues rose by 12.4%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- Compared to its closing price of one year ago, DYAX's share price has jumped by 135.60%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
- The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Biotechnology industry and the overall market, DYAX CORP's return on equity significantly trails that of both the industry average and the S&P 500.
- DYAX CORP has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, DYAX CORP continued to lose money by earning -$0.10 versus -$0.27 in the prior year. For the next year, the market is expecting a contraction of 170.0% in earnings (-$0.27 versus -$0.10).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 1333.9% when compared to the same quarter one year ago, falling from -$0.82 million to -$11.70 million.
- You can view the full Dyax Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.